Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 2/2014

01-02-2014 | Letter to the Editors

Could increased IgA induced by BAFF be the cause of IgA nephropathy development in Behcet’s disease?

Comment on: Behcet’s disease and IgA nephropathy (Rheumatol Int. 2012 Jul; 32(7):2227–9)

Authors: Se Jin Park, Ji Young Oh, Jae Il Shin

Published in: Rheumatology International | Issue 2/2014

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Altay M, Secilmis S, Unverdi S, Ceri M, Duranay M (2012) Behcet’s disease and IgA nephropathy. Rheumatol Int 32:2227–2229PubMedCrossRef
2.
Scully C, Boyle P, Yap PL (1982) Immunoglobulins G, M, A, D and E in Behcet’s syndrome. Clin Chim Acta 120:237–242PubMedCrossRef
3.
Fortune F, Walker J, Lehner T (1990) The expression of gamma delta T cell receptor and the prevalence of primed, activated and IgA-bound T cells in Behçet’s syndrome. Clin Exp Immunol 82:326–332PubMedCentralPubMedCrossRef
4.
5.
McCarthy DD, Chiu S, Gao Y, Summers-deLuca LE, Gommerman JL (2006) BAFF induces a hyper-IgA syndrome in the intestinal lamina propria concomitant with IgA deposition in the kidney independent of light. Cell Immunol 241:85–94PubMedCrossRef
6.
McCarthy DD, Kujawa J, Wilson C, Papandile A, Poreci U, Porfilio EA, Ward L, Lawson MA, Macpherson AJ, McCoy KD, Pei Y, Novak L, Lee JY, Julian BA, Novak J, Ranger A, Gommerman JL, Browning JL (2011) Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy. J Clin Invest 121:3991–4002PubMedCentralPubMedCrossRef
7.
Hamzaoui K, Houman H, Ben Dhifallah I, Kamoun M, Hamzaoui A (2008) Serum BAFF levels and skin mRNA expression in patients with Behçet’s disease. Clin Exp Rheumatol 26(4 Suppl 50):S64–S71PubMed
8.
Xin G, Shi W, Xu LX, Su Y, Yan LJ, Li KS (2012) Serum BAFF is elevated in patients with IgA nephropathy and associated with clinical and histopathological features. J Nephrol doi:10.​5301/​jn.​5000218 [Epub ahead of print]
Metadata
Title
Could increased IgA induced by BAFF be the cause of IgA nephropathy development in Behcet’s disease?
Comment on: Behcet’s disease and IgA nephropathy (Rheumatol Int. 2012 Jul; 32(7):2227–9)
Authors
Se Jin Park
Ji Young Oh
Jae Il Shin
Publication date
01-02-2014
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 2/2014
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-013-2667-6

Other articles of this Issue 2/2014

Rheumatology International 2/2014 Go to the issue

Original Article

Improvement of plasma endothelin-1 and nitric oxide in patients with systemic sclerosis by bosentan therapy

Original Article

Validation of a Persian version of the Fibromyalgia Impact Questionnaire (FIQ-P)

Original Article

Patients with the most advanced rheumatoid arthritis remain with Th1 systemic defects after TNF inhibitors treatment despite clinical improvement

Letter to the Editors

Comment on: Oxidative stress in erythrocytes from patients with rheumatoid arthritis

Original Article

Standards of care for patients with spondyloarthritis

Original Article

Increased risk of stroke among patients with ankylosing spondylitis: a population-based matched-cohort study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits